Cancer Research And Biostatistics (CRAB) is a non-profit organization whose purpose is to help conquer cancer and other diseases through the application of biostatistical principles and innovative data management methods.
The year 2013 was an eventful one. Many great things have happened. After a national search our own Dr. Antje Hoering was promoted to Chief Scientific Officer. This wonderful outcome ends the hunt for hiring for the second of the three hats I have worn: SWOG Group Statistician, CRAB CSO, CRAB CEO. The search for a successor for the CEO position, and the successor to Cay’s CFO position, are fully underway in 2013. We have confidence that both positions will be filled in 2014.

Great work continues at CRAB with progress in our helping to develop novel treatments for lung cancer including our first patients in two investigator initiated trials, partnering on important advances in pancreatic cancer, and making such huge progress in the understanding and treatment of myeloma that the word cure is being used.

Since the formation of CRAB there has been the possibility that the Cooperative Groups, funded by the National Cancer Institute, would be disbanded. Instead, this year, the NCI determined they would provide support for the five most successful of the ten Cooperative Groups. There was a head to head competition to see which groups would survive. Our joint application with Fred Hutchinson Cancer Research Center to the National Cancer Trials Network to be the Statistics and Data Management Center for SWOG was exceedingly well received. This assures that SWOG will survive and will continue to be an important part of the future of CRAB. At the end of the 2013, a similar application was submitted to be the Statistical and Data Management Center for another reorganized initiative, the National Community Oncology Research Program, and we await the reviews with confidence. Like every other nonprofit research institute in the country, we have had our financial difficulties in the past year. We have every expectation, based on SWOG and several other opportunities described in this Report, that 2014 will be the start of a financial turn-around for CRAB.

I would like to take this opportunity to thank all CRAB supporters, our employees, Board of Director members and all of our Friends of CRAB for your loyal support not just in 2013 but for all of the last 15 years that CRAB has been in existence. We could not have made it this far without all of your support and we are looking forward to our future with optimism.

Joe Crowley
## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAB/SWOG: Changing the Way We Treat Cancer</td>
<td>6</td>
</tr>
<tr>
<td>Myeloma: Fighting for a Cure</td>
<td>7</td>
</tr>
<tr>
<td>Leukemia: Pivotal Treatment – Clinical Trial Underway</td>
<td>8</td>
</tr>
<tr>
<td>Pancreatic: Moving the Bar on Survival</td>
<td>9</td>
</tr>
<tr>
<td>Lung: Stage, Sequence, and Stand to Conquer</td>
<td>11</td>
</tr>
<tr>
<td>CRAB Academy: Sharing What We Know – To Change What We Can Do</td>
<td>13</td>
</tr>
<tr>
<td>Leadership: Establishing the Statistical Legacy</td>
<td>14</td>
</tr>
<tr>
<td>Community: Reaching Out – Reaching Up</td>
<td>16</td>
</tr>
<tr>
<td>Financial Report</td>
<td>18</td>
</tr>
</tbody>
</table>

---

### CRAB - Improving Cancer Patient Survival

Cancer Research And Biostatistics (CRAB) leverages its experience in cancer clinical research to advance the standard of care for cancer patients. By expanding our participation in cancer research, we can have a broader impact on cancer prevention and treatment. Dedicated to cancer patients, our focus is on quality clinical trials that deliver results used to identify targeted treatment options, prevention strategies, and ultimately improve survival from cancer. Some 40 years since the War on Cancer was proclaimed, we strive to take cancer off the list for most common cause of death around the world.
CRAB and SWOG: Changing the Way We Treat Cancer

Strength for CRAB Partnerships:

CRAB is an integral part of the research function of SWOG, a cancer research group funded by the National Cancer Institute that exists to design and conduct clinical trials with the goal of improving the practice of medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors.

CRAB is proud to have worked in partnership with SWOG and to have received a high score for SWOG’s participation in the new National Clinical Trials Network (NCTN) program starting in March of 2014. The SWOG Statistical and Data Management Center (SDMC) is co-located at CRAB and FHCRC.

NCTN reviewers wrote that SWOG’s proposed SDMC “will have high impact due to the strong statistics and data management programs to support the SWOG clinical trials. This is an excellent application with numerous strengths... and the research objectives reflect a strong understanding of the issues facing cancer research today.”

THE MEASUREMENT OF THE SWOG DATA MANAGEMENT CENTER

In 2013, CRAB, in partnership with SWOG, had the following successes:

- Activation of 7 SWOG-led trials.
- Enrollment of 6,032 patients with strong accrual in breast, gastrointestinal, genitourinary and symptom control/quality of life studies.
- 24,438 patient vital status updates.
- 12,526 patient data evaluations completed to confirm conformity to protocol requirements and assess side effects, treatment, and response information.
- 37 new institutions, 472 investigators and 975 research support staff were added to the SWOG database and now contribute to SWOG research.
- Over 200 oncology research professionals were trained as part of the Clinical Trials Training Course managed by the Data Operations Department of SWOG at CRAB.
- Publication of 79 articles.
- 15,503 SELECT participants received telephone calls requesting a health update.
- 12,844 health updates were received by either telephone or secure Web submission.

CRAB Completes RAVE Oracle Database Transfer

In 2013, the automated Rave transfer to its Oracle database was completed. All data collected for SWOG via Rave was merged into the SWOG Oracle database to become a part of the data collection of all SWOG trials.

This was a huge project that required mapping Rave and SWOG’s vast and complex database with more than 20 years of historical SWOG data. Resolving the differences between the RAVE Microsoft SQL and SWOG Oracle databases couldn’t have been done without a lot of persistence, hard work, and a talented group of people.
CRAB’s Contributions to MIRT Research

In 2013 CRAB performed a broad range of analyses in collaboration with the Myeloma Institute for Research and Therapy (MIRT) to bring new hope to multiple myeloma patients. CRAB’s expertise in the analysis of clinical research data and gene expression profiling data, resulted in the development of a new risk score based on the expression of five genes that has proven to be a very robust prognostic indicator. CRAB’s contributions to MIRT’s research with analyses like this and statistical models predicting myeloma cure are helping to change the perception of multiple myeloma.

Modeling for a Cure in Multiple Myeloma

More than 1.6 million people in the US received a new cancer diagnosis during 2013 and cancer remains the second most common cause of death in the US. However, throughout 2013 CRAB has worked with researchers at the Myeloma Institute for Research and Therapy (MIRT) to bring new hope to multiple myeloma patients. Myeloma has long carried the brand of an incurable malignancy. However, this concept is not compatible with data from the Total Therapy (TT) trials at MIRT. Nearly 10% of the patients enrolled in their TT1 trial are alive and progression-free, with 14 progression-free for more than 20 years. Statistical models prepared by CRAB to estimate the fraction of patients cured suggest the proportion ranges from around 9% in TT1 to 33% in TT3a. There’s still more work to be done, but CRAB’s work is changing the perception of multiple myeloma.
AML: Registration Trial for Leading Edge therapies

CRAB successfully launched its first registration trial in secondary Acute Myeloid Leukemia (sAML). The new agent under investigation showed promising activity in the phase II setting. This is a randomized phase III pivotal trial with the primary objective to assess overall survival testing this new agent. All departments of CRAB had to develop and implement new procedures and documentation to comply with the regulatory rigor and in-depth validation requirements imposed by the FDA. These requirements are governed by 21 CFR Part 11 of the Federal Regulations. This was a major accomplishment for CRAB to be able to conduct fully 21 CFR part 11 compliant studies. In addition, the CRAB statistical team prepared the first DSMB report and the first DSMC meeting was successfully held in December 2013.

CRAB Cares Takes the Big Climb

CRAB employees from across the organization climbed 69 flights of stairs (1,311 steps) and 788 feet of vertical elevation on March 24 for the 2013 Seattle Big Climb. Together, the “CRABby Climbers” raised over $6,000 in the fight to conquer and cure blood cancers. (Team picture shown).
Pancreatic Cancer

Moving the Bar on Survival

Clinical Trials for Pancreas Cancer

The Pancreatic Cancer Research Team (PCRT) is a consortium of more than 45 clinics worldwide focused on the rapid development of novel therapeutics for pancreatic cancer. Founded in 2003 by thought leaders in pancreatic cancer clinical research, including world-renowned pancreatic cancer experts Dr. Daniel Von Hoff and Dr. Manuel Hidalgo, the consortium is a premier resource for biotech and pharmaceutical companies looking to develop new agents for patients with pancreas cancer.

The first study created by and run through the PCRT that was exclusively funded by the TGen Foundation through the generous support of the Seena Magowitz Foundation is a clinical study for front-line treatment of metastatic pancreatic cancer patients.

The “Seena” Study #1, named after Seena Magowitz who passed away of pancreatic cancer in 2001, and whose Foundation funded the trial, was expanded in 2013 to include an additional 30 patients, for a total of 61 patients over 3 years.

It is a study that offers Abraxane/Gemcitabine and FOLFIRINOX (or FOLFIRI) treatments in different dosing schedules. A genetic analysis (molecular profiling) of any residual tumor after chemotherapy was also included to aid in the determination of the next course of therapy for participants. Study results on the first 31 patients were presented at the ASCO GI Symposium in January 2013 in San Francisco, CA. We expect to complete enrollment and report on the full study results in 2014.

SU2C Dream Team Continues the Fight

CRAB continues its important role as the statistics and data management center for the Stand Up To Cancer (SU2C) Pancreatic Cancer Dream Team.

The combination of nab-paclitaxel (Abraxane) plus gemcitabine reported by this Dream Team to significantly improve overall survival in advanced pancreatic cancer by almost 2 months, is now FDA approved as a first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
CRAB Cares - Purple Stride

On November 3, 2013, CRAB staff members joined tens of thousands of people nationwide in participating in a local 5k run/walk with one common goal – to end pancreatic cancer. The Puget Sound PurpleStride served as an opportunity to honor survivors and remember loved ones, and most importantly, to make a difference in the fight against pancreatic cancer. The event raised $225,544 for pancreatic cancer research, nearly $19,000 above its goal! Throughout the U.S., PurpleStride events contribute millions of dollars to advance research, support patients and create hope. CRAB was honored to participate - look for the CRABCares team at Magnuson Park again in 2014!
Recognizing an Urgent Need – CRAB’s CTC

Recognizing the urgent need to improve survival rates for lung cancer patients, CRAB created the Clinical Trials (CTC) for Lung Cancer. Our Consortium seeks to better understand lung cancer and in doing so identify more effective treatment options. Fighting lung cancer one clinical trial at a time, the CRAB CTC uses advancements in the fields of laboratory testing and drug development to find treatments that are both safe and effective.

In early December 2013, CRAB announced enrollment of the first patient into the inaugural clinical trial sponsored by its Clinical Trials Consortium (CTC). The mission of the CRAB CTC is to ensure rapid clinical testing of new and innovative cancer treatments, and is focusing on lung cancer. By engaging frontline treating oncologists to push the boundaries of patient care, the aim is to improve the standard of care and extend overall survival. The trial is being funded by Onyx Pharmaceuticals, Inc., an Amgen subsidiary.

Key Collaboration: CRAB and the IASLC

CRAB continues its collaboration with the IASLC and plays a key role in the development of the 8th edition of the International Association Study of Lung Cancer Staging manual in Thoracic Oncology. CRAB was invited to attend the 15th annual World Congress on Lung Cancer and participated in the Staging committee meetings for Lung Mesothelioma and Thymic malignancies.

As a partner in the International Association for the Study of Lung Cancer (IASLC), lung cancer staging was developed based on more than 100,000 cases of lung cancer gathered from around the world and analyzed by CRAB scientists.

“The International Association for the Study of Lung Cancer (IASLC) has as its mission the worldwide eradication of lung cancer and all thoracic malignancies. Our collaboration with Cancer Research And Biostatistics (CRAB) spans over 13 years and their expertise and commitment have helped us in this struggle. As President of the IASLC, I realize that there is still much to be achieved and commend this initiative by CRAB as worthy of your support”. - Peter Goldstraw, MB, ChB, FRCS, President, International Association for the Study of Lung Cancer
In 2013, CRAB and SWOG made headlines in The Economist, Forbes and international science journals as they embarked on a groundbreaking journey with the National Cancer Institute (NCI). The SWOG Data Management Center at CRAB is coordinating data collection efforts for a Lung Master Protocol (Lung-MAP), a phase II and phase III advanced squamous cell lung cancer trial. This work includes the creation, storage and protection of data associated with this exciting new trial. CRAB will hold the database for SWOG, keeping the data confidential and current. CRAB will build the forms, create the edit checks, perform all tests, maintain validation, guide and train participating institutions on forms submission and completion. SWOG will partner in this effort with all the adult-cancer cooperative groups in North America. Patients will be assigned to therapy based on the molecular characteristics of their disease. The preparation effort in 2013 to design the trial’s inner workings was massive. All CRAB departments have touched this project. Accrual will be open to sites that participate in the NCI’s National Clinical Trials Network. Lung-MAP is designed to enroll approximately 1,250 patients per year while testing five drugs simultaneously. This approach will greatly reduce the costs in time and money to develop targeted drug therapies for squamous cell lung cancer. We are proud to work on this important clinical trial and look forward to its activation in 2014.

CRAB Understands Volumes
CRAB’s world-class research brought depth in staging and treatment decisions for mesothelioma through the coordination and analysis of a large pilot study. The Pilot Study of the Use of Tumor Volume Measurement from CT Scans for the Clinical Staging of Malignant Pleural Mesothelioma (MPM) hopes to establish a standardized method for clinicians to conduct three-dimensional CT scans and to use volume measurement data to enhance the staging and classification of newly diagnosed MPM.

Institutional review board (IRB) review for the study began in August and will be followed by data collection, data submission and query work September through March 2014. Data analysis will occur March to June 2014, when CRAB will initiate a grant application for a larger international study.

Raising Awareness and Joining the Fight Against Lung Cancer
On September 7, 2013, CRAB employees participated in the Free to Breathe 5K Run/Walk & 1-Mile Walk event. The event featured 404 participants who raised over $55,000 to support lung cancer research. The CRABCares mission is aligned with the goal of such events: to support community efforts in the fight to prevent and cure cancer.
CRAB Welcomes SWOG’s Young Investigators

The SWOG Young Investigators Training Course occurs every September at Cancer Research And Biostatistics. Young Investigators are selected through an application process after which they are trained in protocol development and statistical considerations of study design, with the expectation that the study developed by each participating investigator will be implemented in SWOG. This program, and CRAB’s role in the facilitation, has proven to be important in the research and career development for participants.

CRAB Welcomes SWOG’s Young Investigators

CRAB Academy

Showcasing our Clinical Trial Expertise

CRAB, in partnership with a multi site Cancer Treatment Center, hosted a two-day clinical training course in our Seattle office this past October. Thirteen employees, from various sites, participated in the course along with Dr. Ron Korn from Imaging Endpoints. CRAB’s very own Dr. John Crowley taught the workshop course on the “Basics of Cancer Clinical Trials” with Dr. Antje Hoering presenting on Phase I, II, and III trials. Together, Drs. Crowley and Hoering presented on the design and monitoring of Phase III trials. A unique opportunity to showcase CRAB’s clinical trial expertise, we look forward to partnering with this and similar groups on future clinical trials training workshops.

Success at the Group Meeting: Conducting the CTTC

Since 2003, staff of CRAB’s Data Management Department representing the Data Operations Center of SWOG, has conducted and coordinated the Clinical Trials Training Course (CTTC) held at the SWOG Group Meetings. Presentations at the CTTC provide an overview of SWOG, as well as information pertaining to topics such as the explanation of clinical trials, phases of studies, quality control, quality assurance, ethics and quality of life. Familiarization with the SWOG registration process, forms, and office procedures is included along with a practicum round-table discussion providing participants with practice of forms completion, adverse event grading, response assessments, and calculating laboratory values. In 2013, CRAB conducted two successful workshops at the Group Meetings in Chicago and San Francisco.
Antje Hoering – Leadership and Scientific Direction

In January 2013 CRAB announced the appointment of Antje Hoering, PhD to the position of Chief Scientific Officer. Dr. Hoering guides the scientific direction of CRAB while it seeks to expand current and future collaborations with cancer centers, clinical research consortia, private industry, and non-profit groups involved in oncology clinical trials.

Dr. Hoering reports to John Crowley, PhD, Chief Executive Officer, a leader in the development and application of biostatistical methods to improve oncology clinical research. “Appointing Antje to the CSO role is a reflection of the immense respect I have for her expertise and commitment to improve oncology patient outcomes,” Dr. Crowley provided in a statement. “In this expanded role, she will provide her leadership across the organization, and further develop the impact CRAB can have on helping to conquer cancer.”

UW Awards Dr. Crowley for Biostatistical Contributions

John Crowley, PhD, President and CEO of CRAB, was awarded the distinguished 2013 Norman E. Breslow Lectureship from the University of Washington’s School of Public Health. Dr. Crowley, a colleague and former student of Dr. Breslow, was especially honored to receive the award. Dr. Crowley delivered his lecture “A Brief History of Survival Analysis” at the Lectureship event in August.

The Norman E. Breslow Distinguished Lectureship was established in 2006 to honor the instrumental scientific contributions of Norman E. Breslow in the Department of Biostatistics of the School of Public Health and Community Medicine. The Lectureship is awarded annually to an individual who has made important contributions to the advancement of biostatistical methodology and its applications in the health sciences. Former Breslow Lecturers include Mitchell H. Gail of the National Cancer Institute and David Clayton of Cambridge University.
CRAB Welcomes Dr. Lynn Shemanski

In late 2013, Lynn Shemanski, PhD, joined the CRAB Statistical team as a Senior Biostatistician. Dr. Shemanski specializes in Clinical Research Services projects and provides statistical oversight for the Stand Up to Cancer Pancreatic Cancer Research Team and Clinical Trial Consortium projects.

Dr. Shemanski received her Master’s Degree in Statistics from UC-Berkeley, and her PhD in Biostatistics from the University of North Carolina at Chapel Hill. She has more than 25 years’ experience working in clinical trials. Prior to joining CRAB, Dr. Shemanski was the Director of Biostatistics at Poniard Pharmaceuticals and Director of Biometrics at Zymogenetics, a subsidiary of Bristol-Myers Squibb. In these capacities, Lynn supervised statistical programmers and data management personnel and served as primary statistician on many clinical trials in oncology.

In her own words: “I am excited to work at CRAB because it is so clear that everyone here cares about their impact on cancer patients. The mix of research and industry projects plays to my strengths in a way that allows me to make a positive contribution to ongoing and future CRAB projects.”

Dr. Michael LeBlanc Brings Extensive Experience to our Board

CRAB was pleased to welcome Michael LeBlanc to the CRAB Board of Directors in 2013. Dr. LeBlanc is a full member of the Fred Hutchinson Cancer Research Center, a Research Professor of Biostatistics at the University of Washington and both the current Group Statistician and Principal Investigator of the SWOG Statistical Center Grant (Cooperative Agreement Award No. 5 U10 CA038926-27). He brings extensive experience in the design and analysis of clinical trials and a significant personal research record in clinical trials and adaptive regression methods relevant to the analysis of clinical trials and cohort data.

Dr. LeBlanc’s collaborative research focuses on statistical activities related to Phase II and Phase III clinical trials. His research interests include the design and analysis of clinical trials, methods for exploratory analysis of survival data and adaptive non-parametric regression. Most of his research focuses on the design, analysis and conduct of therapeutic clinical trials. Dr. LeBlanc holds a Ph.D. from the University of Washington and a Masters in Mathematics from the University of Waterloo.

Distinguished Harvard University Honors for CRAB Founder

In 2013 John Crowley, PhD, President and CEO of CRAB, was chosen to receive the Marvin Zelen Leadership Award in Statistical Science. Dr. Zelen is world-renowned for development of clinical cancer trial methodologies, among other foundational advancements in biostatistics.

The award, granted by the Harvard School of Public Health in the name and spirit of Dr. Zelen, recognizes an individual in government, industry or academia who by virtue of his or her outstanding leadership has greatly impacted the theory and practice of statistical science. The most distinguishing criterion is the awardee’s contribution to the creation of an environment in which statistical science and its applications have flourished. Dr. Crowley was deeply honored to receive the award and delivered a public lecture on statistical science at the Harvard School of Public Health, where he was presented with a citation and an honorarium.

Leadership Transitions: CEO Search Underway

As an integral part of CRAB’s plan for transition of leadership from CRAB’s founders, we kicked off the process to find a successor for CEO and co-founder Dr. John Crowley. In April, the CEO Search Committee, made up of five Board members, including Dr. Crowley, and two of CRAB’s Officers, hired Korn/Ferry to conduct a candidate search. The search focused on candidates with oncology-related scientific expertise, particularly biostatisticians. Under the direction of Dr. Warren Ross, Korn/Ferry initiated the search in April and identified several who applied for the position. Interviews with five candidates were conducted from August through December through three progressive rounds. No hiring decision was made in 2013. Heading into 2014, the CRAB Board of Directors will evaluate the search and plan the next steps.
Thank You Friends and Supporters!

Conquering cancer is a goal shared by many of us. Cancer Research And Biostatistics is pleased to recognize the donors, volunteers and sponsors who joined us in 2013 in the fight to cure cancer.

We express our sincere gratitude to the generous contributions from all our donors, including our corporate partners. In addition to creating a positive impact on the community and enriching the lives of others, philanthropic support from workplace giving and customer community programs, not only helps CRAB advance research and the standard of care for cancer patients, it helps improve treatment for many cancer types.

We would like to thank the following corporate and government giving programs that helped fund CRAB in 2013.

- Amazon
- Boeing
- Combined Federal Campaign (CFC)
- Costco
- Fred Meyer
- King County Government
- Microsoft
- Seattle Foundation
- Target

We’re in the fight to conquer cancer. Do you want to help?

Building on decades of experience, CRAB’s leadership in clinical research has helped improve treatment of many cancer types. CRAB supports cancer clinical research around the globe - and in our backyard in Seattle.

We provide services to organizations conducting ground-breaking research that has changed the face of cancer. Through these collaborations, CRAB has touched the lives of millions of patients diagnosed with cancer.

When you donate to CRAB, you become a partner with our leading statisticians, researchers, and clinical site managers in this shared fight against cancer.

In 2013, CRAB donors funded:

- The collection of essential patient data to understand if new cancer drugs are effective.
- The introduction of new drugs to cancer patients in clinical trials.
- An important collaboration with key members of a local cancer awareness advocacy group to better understand cancer survival and compliance with a new government mandate.

We look forward to your continued support and welcome your contributions year-round. You can find more information about CRAB at www.CRAB.org, along with a secure online donation link.

Thank you for supporting our mission and standing with CRAB in our belief that “Every Cancer Patient Counts”.

The Art Institute and the “Why” of CRAB

CRAB partnered with students from the Art Institute of Seattle’s Revolution Studios winter 2013 video production class to produce a video that accurately captures the work we’re doing at CRAB and brings our vision to life in a very real and meaningful way. The student-led production conveys a deep understanding of CRAB’s rich history and our role in helping cure cancer. You can check out our video story at www.crab.org.

Community Connections

We are fortunate to be part of a greater community that gives back, pays forward, and shares in the burden of improving the lives of others. This year CRAB created CRABCares, an employee-led program that promotes staff participation in events that align with our mission to prevent and cure cancer. CRABCares builds collaboration within CRAB and with the community we serve. We participate in events ranging from fundraising runs/walks to advocacy and educational opportunities.

In 2013, CRAB staff, partners and stakeholders lent their time, support and funds to the Big Climb at Seattle’s Columbia Tower to support the Leukemia and Lymphoma Society, the Free to Breathe Run/Walk for lung cancer research and the Pancreatic Cancer Action Network’s Purple Stride event. We were proud to see employees connecting with the community, especially with those impacted by cancer.

Partners in Expertise

In conjunction with other life science non-profits CRAB formed a strategic round-table discussion series, the Pacific Northwest Life Sciences Executive Forum. The Forum is designed to bring together non-profit corporate-level professionals with a diversity of expertise in the life sciences non-profit community to exchange ideas, build regional collaborative partnerships and to empower local scientific research.

In 2013, the Forum met to discuss ways to maximize impact in life sciences business development in the midst of economic challenges. CRAB looks forward to expanding Forum-level collaborations and partnerships with focus on brand awareness, increasing CRAB’s participation in this community and visibility.
The impact on CRAB of the financial crisis and sequestration continued in 2013. Our revenue dipped lower than 2012, equaling that of 2008. The loss in revenue resulted from a continued decrease in federally and privately funded SWOG activity. Revenue from all SWOG sources continued to fall from a high of $8,157,188 in 2009 to only $5,435,678 in 2013.

We increased our revenue in our Clinical Research and Statistical Research Program (CRSR) to offset this decline, such that 43% of revenue in 2013 was from sources other than SWOG as opposed to 27% in 2009. However these diversification efforts were not enough to counteract the loss of SWOG activity. As difficult as this trend in revenue has been, 2014 looks to be promising for CRAB. Most notably, the reorganization of funding for the national cooperative groups like SWOG should increase CRAB’s federal funding, and new SWOG projects are being supported by pharmaceutical companies. We anticipate non SWOG revenues to remain strong in 2014 and for SWOG funding to increase markedly.

### SUPPORT & REVENUE

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant</td>
<td>5,415,172</td>
<td>6,158,620</td>
<td>7,015,304</td>
<td>6,866,894</td>
<td>7,067,393</td>
</tr>
<tr>
<td>Contract</td>
<td>4,070,928</td>
<td>3,552,971</td>
<td>3,070,709</td>
<td>3,340,806</td>
<td>3,922,770</td>
</tr>
<tr>
<td>Workshop</td>
<td>26,088</td>
<td>32,318</td>
<td>16,513</td>
<td>17,949</td>
<td>41,085</td>
</tr>
<tr>
<td>Contributions</td>
<td>11,147</td>
<td>46,101</td>
<td>18,773</td>
<td>15,441</td>
<td>71,298</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 9,523,335</strong></td>
<td><strong>$ 9,790,010</strong></td>
<td><strong>$ 10,121,299</strong></td>
<td><strong>$ 10,241,090</strong></td>
<td><strong>$ 11,102,546</strong></td>
</tr>
</tbody>
</table>

### OPERATING EXPENSES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>7,469,156</td>
<td>7,485,583</td>
<td>7,677,869</td>
<td>7,450,747</td>
<td>7,406,752</td>
</tr>
<tr>
<td>Workshop</td>
<td>20,764</td>
<td>32,318</td>
<td>16,513</td>
<td>17,950</td>
<td>41,095</td>
</tr>
<tr>
<td>Administration</td>
<td>2,903,616</td>
<td>2,821,290</td>
<td>2,818,364</td>
<td>2,805,096</td>
<td>2,553,576</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 10,393,536</strong></td>
<td><strong>$ 10,339,191</strong></td>
<td><strong>$ 10,512,746</strong></td>
<td><strong>$ 10,273,793</strong></td>
<td><strong>$ 10,001,423</strong></td>
</tr>
</tbody>
</table>
## 2013 Leadership and Governance

### Board of Directors
- John Crowley
- Cynthia Adkins
- Patricia Beckmann
- Glenn Chinn
- Frank Curci
- Susan Finneran
- Gary Goodman
- David Gray
- Michael LeBlanc
- Candice McCoy

### Officers
- John Crowley
  - President and CEO
- Tammy Buist
  - Vice President
  - Secretary
  - Chief Business Development Officer
- Catherine Crowley
  - Vice President
  - Treasurer
  - Chief Financial Officer
- Keith Goodman
  - Vice President
  - Chief Technology Officer
- Antje Hoering
  - Vice President
  - Chief Scientific Officer
- Evonne Lackey
  - First Vice President
  - Chief Data Management Officer